Navigation Links
MiMedx Group, Inc. Board Announces Support for Chairman Parker H. "Pete" Petit

KENNESAW, Ga., Jan. 11, 2012 /PRNewswire/ -- The Board of Directors of MiMedx Group, Inc. (OTCBB: MDXG), announced today that the Board of Directors fully supports the Company's Chairman and CEO, Parker H. "Pete" Petit, despite the action taken today by the Securities Exchange Commission ("SEC").

The SEC has brought a civil action against Mr. Petit alleging that in 2007, when he was Chairman and CEO of Matria Healthcare, Inc. (formerly listed on NASDAQ), he provided inside information to a friend who subsequently purchased Matria Healthcare stock.  Mr. Petit's attorneys issued a press release regarding this matter earlier today.

Larry W. Papasan, Chairman of the Nominating and Governance Committee of MiMedx's Board, stated, "The independent members of Board of Directors have  reviewed  this situation very closely and are not aware of any direct evidence that would implicate Mr. Petit in any wrongdoing. There is no assertion of any issues on the part of MiMedx, and the independent directors believe that Mr. Petit can continue his able leadership of MiMedx while dealing with this personal, civil matter.  Mr. Petit is a great leader and an outstanding business executive. His lifelong legacy of business accomplishments, civic involvement and philanthropy is exemplary and representative of the highest moral and ethical standards. The Board believes Mr. Petit is deserving of every benefit of the doubt, and, barring unforeseen circumstances or material new developments, looks forward to many more years in which MiMedx and its shareholders will benefit from his leadership and vision."

"The MiMedx Board of Directors and management team are keenly focused on the exciting opportunities ahead of our Company and will continue to dedicate all of our resources to fulfilling our potential," added Papasan.

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 60,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Group, Inc. to Present at the Noble Capital Markets 8th Annual Equity Conference
2. MiMedx Group Receives HCPCS C-Code from Medicare for EpiFix® Reimbursement
3. MiMedx Group Announces Third Quarter 2011 Results
4. MiMedx Groups EpiFix® Receives American Podiatric Medical Association Seal of Approval
5. MiMedx Group Partners With Affirmative Solutions
6. MiMedx Group Receives FDA Clearance to Market Its HydroFix™ Ortho Shield™ Device
7. MiMedx Announces Launch of AmnioFix™ Nerve Wrap
8. MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting
9. MiMedx Group, Inc. Announces Release Date for First Quarter Results
10. MiMedx Completes Acquisition of Surgical Biologics
11. MiMedx Receives Additional CE Certification for Its HydroFix™ Technology
Post Your Comments:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):